UvA-DARE (Digital Academic Repository)

Immediate versus deferred coronary angioplasty in non-ST-elevation acute coronary syndromes: Reply

Riezebos, R.K.; Laarman, G.J.; Tijssen, J.G.P.

DOI

[10.1136/hrt.2009.175430](https://doi.org/10.1136/hrt.2009.175430)

Publication date

2009

Document Version

Final published version

Published in

Heart

[Link to publication](#)

Citation for published version (APA):

Riezebos, R. K., Laarman, G. J., & Tijssen, J. G. P. (2009). Immediate versus deferred coronary angioplasty in non-ST-elevation acute coronary syndromes: Reply. *Heart*, 95(17), 1456. <https://doi.org/10.1136/hrt.2009.175430>

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

UvA-DARE is a service provided by the library of the University of Amsterdam (<https://dare.uva.nl>)

The authors' reply

R K Riezebos, G J Laarman and J G P Tijssen

Heart 2009 95: 1456

doi: 10.1136/hrt.2009.175430

Updated information and services can be found at:

<http://heart.bmj.com/content/95/17/1456.full.html>

These include:

References

This article cites 6 articles, 5 of which can be accessed free at:

<http://heart.bmj.com/content/95/17/1456.full.html#ref-list-1>

Article cited in:

<http://heart.bmj.com/content/95/17/1456.full.html#related-urls>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

[Hypertension](#) (12368 articles)

[Interventional cardiology](#) (7250 articles)

[Percutaneous intervention](#) (487 articles)

[Epidemiology](#) (5270 articles)

Notes

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://journals.bmj.com/cgi/ep>

Featured correspondence

reducing periprocedural MI are well documented.^{6,7}

The results of this study must be interpreted with caution and any change in clinical practice resisted until alternative methods of assessing periprocedural MI (eg, novel biomarkers like N-terminal pro-B-type natriuretic peptide,⁸ intra-coronary multi-channel ECG recording⁹ and myocardial scintigraphy) and the optimal timing of coronary intervention have been further evaluated in patients with ACS. Newer antithrombotic and second-generation antiplatelet agents may also confer benefit in this situation.

A Kumar, D H Roberts

Lancashire Cardiac Centre, BFW Hospitals NHS Trust, Blackpool, UK

Correspondence to: Dr A Kumar, Department of Cardiology, Lancashire Cardiac Centre, BFW Hospitals NHS Trust, Whinney Heys Road, Blackpool FY3 8NR, UK; dr.kumar2@bfwhospitals.nhs.uk

Competing interests: None.

Heart 2009;**95**:1455–1456. doi:10.1136/hrt.2009.174466

REFERENCES

1. **Riezebos RK**, Ronner E, ter Bals E, *et al*. Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes. *Heart* 2009;**95**:807–12.
2. **Cutlip DE**, Kuntz RE. Cardiac enzyme elevation after successful percutaneous coronary intervention is not an independent predictor of adverse outcomes. *Circulation* 2005;**112**:916–23.
3. **Abdelmeguid AE**, Topol EJ, Whitlow PL, *et al*. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. *Circulation* 1996;**94**:1528–36.
4. **Ellis SG**, Chew D, Chan A, *et al*. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. *Circulation* 2002;**106**:1205–10.
5. **Patti G**, Colonna G, Pasceri V, *et al*. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. *Circulation* 2005;**111**:2099–106.
6. **Patti G**, Pasceri V, Colonna G, *et al*. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. *J Am Coll Cardiol* 2007;**49**:1272–8.

7. **Clergeau MR**, Morello R, Lepage O, *et al*. Statin in prevention of periprocedural myonecrosis after percutaneous coronary angioplasty: systematic review and meta-analysis. *Ann Cardiol Angeiol (Paris)* 2008;**57**:181–6.
8. **Bonaca MP**, Wiviott SD, Sabatine MS, *et al*. Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial). *Am J Cardiol* 2007;**99**:344–8.
9. **Balian V**, Galli M, Marcassa C, *et al*. Intracoronary ST-segment shift soon after elective percutaneous coronary intervention accurately predicts periprocedural myocardial injury. *Circulation* 2006;**114**:1948–54.

The authors' reply: Immediate percutaneous coronary intervention (PCI) is currently thought to be useful for ischaemia at early onset, thereby minimising detrimental consequences of vessel occlusion. By selecting only those patients with onset of chest pain within 6 h (median 3 h) we included a consecutive series of acutely unstable patients. By definition this restricted the inclusion rate.¹

Moreover, the use of creatine kinase-MB as an end point is questioned by Kumar *et al*.² However, meta-analysis showed that less periprocedural tissue necrosis is associated with an improved clinical course.³ This and other evidence led to the consensus that PCI-related ischaemic events have adverse effects on patient outcome.⁴ However, it must be kept in mind that our study was not powered to detect a difference in survival. For this, one would need a trial with at least 10 000 patients to demonstrate an effect on mortality.

In addition, Kumar *et al* point to differences in baseline characteristics which do not favour the immediate PCI group. Although the prevalence of hypertension and previous coronary artery bypass grafting, was higher in the immediate group, adjustment for these differences by multivariate analyses did not alter the results of the study. Other baseline factors like TIMI flow favoured the immediate PCI group.¹

At the time of patient inclusion, a loading dose of 300 mg clopidogrel was customary. Nowadays, the protocol in our hospital is to use a high loading dose when patients apply

for immediate PCI. It is only recently that this practice has been advocated by the cardiac societies.⁵ The addition of abciximab to aspirin and clopidogrel was—wrongly—thought to provide sufficient periprocedural protection in the immediate treated group.⁶ Furthermore, virtually all patients were pretreated with atorvastatin 80 mg.

We agree with the authors that the results of our study should be interpreted with care, in particular because of the small sample size. Nevertheless, we would like to emphasise that there is absolutely no evidence demonstrating the clinical superiority of immediate PCI over the deferred approach (beyond 24 h).

R K Riezebos,¹ G J Laarman,² J G P Tijssen³

¹ Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands;

² King's College Hospital, London, UK; ³ Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

Correspondence to: Dr R K Riezebos, Onze Lieve Vrouwe Gasthuis, Department of Cardiology, PO Box 95500, 1090 HM, Amsterdam, The Netherlands; R.K.Riezebos@xs4all.nl

Heart 2009;**95**:1456. doi:10.1136/hrt.2009.175430

REFERENCES

1. **Riezebos RK**, Ronner E, ter Bals E, *et al*. Immediate versus deferred coronary angioplasty in non-ST-elevation acute coronary syndromes. *Heart* 2009;**95**:807–12.
2. **Kumar A**, Roberts DH. Immediate versus deferred coronary angioplasty in non-ST-elevation acute coronary syndromes. *Heart* 2009;**95**:1456.
3. **Akkerhuis KM**, Alexander JH, Tardiff BE. Minor myocardial damage and prognosis. Are spontaneous and percutaneous coronary intervention related events different? *Circulation* 2002;**105**:554–6.
4. **Thygesen K**, Alpert JS, White HD. Joint ESC/ACC/AHA/WHF task force for the redefinition of myocardial infarction. Universal definition of myocardial infarction. *Eur Heart J* 2007;**28**:2525–38; *Circulation* 2007;**116**:2634–53; *J Am Coll Cardiol* 2007;**50**:2173–95.
5. **Bassand JP**, Hamm CW, Ardissino D, *et al*. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. *Eur Heart J* 2007;**28**:1598–660.
6. **Ronner E**, Boersma E, Akkerhuis KM, *et al*. Patients with acute coronary syndromes without persistent ST-elevation undergoing percutaneous coronary intervention benefit most of early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. *Eur Heart J* 2002;**23**:239–46.